Biotechnology Assets SA
MAD:BST

Watchlist Manager
Biotechnology Assets SA Logo
Biotechnology Assets SA
MAD:BST
Watchlist
Price: 0.28 EUR -3.45%
Market Cap: 18.2m EUR
Have any thoughts about
Biotechnology Assets SA?
Write Note

Biotechnology Assets SA
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biotechnology Assets SA
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Biotechnology Assets SA
MAD:BST
Cost of Revenue
-€804.2k
CAGR 3-Years
17%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Grifols SA
MAD:GRF
Cost of Revenue
-€4.1B
CAGR 3-Years
-10%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Oryzon Genomics SA
MAD:ORY
Cost of Revenue
-€1.1m
CAGR 3-Years
-19%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Pharma Mar SA
MAD:PHM
Cost of Revenue
-€9.3m
CAGR 3-Years
12%
CAGR 5-Years
-11%
CAGR 10-Years
12%
No Stocks Found

Biotechnology Assets SA
Glance View

Market Cap
17.8m EUR
Industry
Biotechnology

Biotechnology Assets SA operates as a biopharmaceutical company. The company is headquartered in Jerez De La Frontera, Cadiz and currently employs 32 full-time employees. The company went IPO on 2011-06-14. The Firm’s main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company, through its subsidiaries, is also present in Luxembourg, Hong Kong and USA.

BST Intrinsic Value
0.29 EUR
Undervaluation 2%
Intrinsic Value
Price

See Also

What is Biotechnology Assets SA's Cost of Revenue?
Cost of Revenue
-804.2k EUR

Based on the financial report for Jun 30, 2024, Biotechnology Assets SA's Cost of Revenue amounts to -804.2k EUR.

What is Biotechnology Assets SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
50%

Over the last year, the Cost of Revenue growth was 31%. The average annual Cost of Revenue growth rates for Biotechnology Assets SA have been 17% over the past three years , 50% over the past five years .

Back to Top